Maksim Labkouski
Actinium Pharmaceuticals (NYSE:ATNM) and Fusion Pharmaceuticals (FUSN) stocks rallied Tuesday following news that fellow radiopharmaceuticals developer RayzeBio (RYZB) has agreed to be acquired by Bristol Myers (BMY) for $4.1B.
Actinium shares were up 15% in early afternoon trading while shares of Fusion shot up 20%.
Actinium, Fusion and RayzeBio are all developing radiotherapies involving the radioisotope actinium-225, or 225Ac.
RayzeBio and Bristol Myers announced the deal early Tuesday.
In a noted released following the deal announcement, RBC Capital analysts said the RayzeBio deal would offer “positive readthrough” to other radiopharmaceutical companies, particularly Fusion.
